Cxbladder® Monitor
De-intensify the surveillance of non-muscle invasive bladder cancer.
Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in non-muscle invasive bladder cancer (NMIBC) patients with a low risk of recurrent disease, improving comfort and compliance.
• Combines both genotypic factors and patient clinical information to reliably rule out those patients with a low probability of urothelial cancer, reducing the frequency of cystoscopy required.
• Spares patients the discomfort, anxiety, risk, and inconvenience of an invasive procedure.
• Improves compliance with scheduled surveillance checks.
• Focuses your in-clinic resources on those that need care.
• Empowers your team and improve time utilisation to maximise overall efficiency.
Not for first-line diagnosis of bladder cancer. Not for high-grade or muscle-invasive bladder cancer surveillance without cystoscopy. Not a replacement for cystoscopy where clinical concern is present.
| Step / Test | Accuracy | Notes |
|---|---|---|
| Sensitivity | 93% | |
| NPV | 97% |
Urine in Cxbladder container
30–50 mL midstream urine collected into the Cxbladder collection tube (contains preservative). Do not use catheter samples.
- First void urine (Only 2nd pass of the day or later is accepted)
- Grossly bloody urine
- Acute UTI (Treat UTI first and delay test for 2 weeks)
- <2 weeks after cystoscopy
- <6 weeks after BCG
Available through Codex Genetics as the authorised Pacific Edge distributor in Hong Kong.
Cxbladder specimens must be collected using the dedicated Cxbladder collection kit.
- Request a collection kit from your healthcare provider or Codex Genetics.
- Collect midstream urine (30–50 mL) into the provided tube with preservative.
- Seal securely; store at room temperature.
- Deliver to Codex Genetics Laboratory within 5 days of collection. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong.
Please contact us for pricing.
- Cxbladder Monitor Score < 3.5
- Low probability of recurrent urothelial carcinoma
- Cxbladder Monitor Score >= 3.5
- Cannot rule out urothelial carcinoma and a clinician-directed protocol to determine if recurrent Urothelial Carcinoma is present is warranted
NMIBC accounts for ~75% of bladder cancer cases. Standard surveillance requires regular cystoscopy, which is invasive, costly, and burdensome for patients. Published clinical studies show Cxbladder Monitor has high sensitivity for detecting recurrence, enabling clinicians to alternate with or substitute cystoscopy in appropriate patients.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
The services provided by Codex Genetics are for research use only, and they are not suitable for diagnostic and/or treatment use, unless otherwise instructed by licensed medical professionals.
除非有醫療專業人員另行指示，此網站的服務只供研究用途，並不供作診斷或治療任何疾病之用。
CoGenesis® is a trademark of Codex Genetics Limited
© 2026 Codex Genetics Limited. All rights reserved.
